Preoperative Metformin May Improve Surgical Outcomes
By HospiMedica International staff writers Posted on 29 Apr 2020 |
A new study suggests that preoperative metformin may be associated with decreased postoperative mortality and readmission in type 2 diabetes (T2D) patients.
Researchers at the University of Pittsburgh School of Medicine (Pitt; PA, USA) and the Veterans Affairs Pittsburgh Healthcare System (PA, USA) conducted a retrospective observational study involving 5,460 patients with T2D who underwent a major surgical procedure at one of 15 community and academic hospitals between 2010 and 2016. The main outcomes and measures were all-cause postoperative mortality, hospital readmission within 90 days of discharge, and preoperative inflammation, with or without preoperative metformin.
The results revealed that preoperative metformin was associated with a 3% 90-day mortality risk in the T2D patients who received preoperative metformin, compared to 5% in those who did not; patients in both groups had the same rate of 30-day mortality (2%). In addition, the 30-day readmission rate was also lower in the preoperative metformin group (11%), than in those without (13%). Preoperative inflammation was also reduced in the metformin group, compared to those without, as measured by mean neutrophil to leukocyte ratio. The study was published on April 8, 2020, in JAMA Surgery.
“This study found an association between metformin prescriptions provided to individuals with type 2 diabetes before a major surgical procedure and reduced risk-adjusted mortality and readmission after the operation,” concluded lead author Katherine Reitz, MD, of the PITT department of surgery, and colleagues, suggesting that “adults with comorbidity have less physiological reserve and an increased rate of postoperative mortality and readmission after the stress of a major surgical intervention.”
Metformin belongs to a class of drugs called biguanides, which inhibit the production of glucose in the liver. In addition to suppressing hepatic glucose production, metformin also increases insulin sensitivity, enhances peripheral glucose uptake, decreases insulin-induced suppression of fatty acid oxidation, and decreases absorption of glucose from the gastrointestinal tract.
Related Links:
University of Pittsburgh School of Medicine
Veterans Affairs Pittsburgh Healthcare System
Researchers at the University of Pittsburgh School of Medicine (Pitt; PA, USA) and the Veterans Affairs Pittsburgh Healthcare System (PA, USA) conducted a retrospective observational study involving 5,460 patients with T2D who underwent a major surgical procedure at one of 15 community and academic hospitals between 2010 and 2016. The main outcomes and measures were all-cause postoperative mortality, hospital readmission within 90 days of discharge, and preoperative inflammation, with or without preoperative metformin.
The results revealed that preoperative metformin was associated with a 3% 90-day mortality risk in the T2D patients who received preoperative metformin, compared to 5% in those who did not; patients in both groups had the same rate of 30-day mortality (2%). In addition, the 30-day readmission rate was also lower in the preoperative metformin group (11%), than in those without (13%). Preoperative inflammation was also reduced in the metformin group, compared to those without, as measured by mean neutrophil to leukocyte ratio. The study was published on April 8, 2020, in JAMA Surgery.
“This study found an association between metformin prescriptions provided to individuals with type 2 diabetes before a major surgical procedure and reduced risk-adjusted mortality and readmission after the operation,” concluded lead author Katherine Reitz, MD, of the PITT department of surgery, and colleagues, suggesting that “adults with comorbidity have less physiological reserve and an increased rate of postoperative mortality and readmission after the stress of a major surgical intervention.”
Metformin belongs to a class of drugs called biguanides, which inhibit the production of glucose in the liver. In addition to suppressing hepatic glucose production, metformin also increases insulin sensitivity, enhances peripheral glucose uptake, decreases insulin-induced suppression of fatty acid oxidation, and decreases absorption of glucose from the gastrointestinal tract.
Related Links:
University of Pittsburgh School of Medicine
Veterans Affairs Pittsburgh Healthcare System
Latest Surgical Techniques News
- Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health
- Tiny Robots Made Out Of Carbon Could Conduct Colonoscopy, Pelvic Exam or Blood Test
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery